Editorial commentary: Infections due to macrolide-resistant mycoplasma pneumoniae: Now what?

Clinical Infectious Diseases

Volumn 55, Issue 12, 2012, Pages 1650-1651

  Bébéar, Cécile ^a,b,c  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b Plate Forme d'Exploration du Métabolisme composante protéomique   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; LEVOFLOXACIN; MACROLIDE; MINOCYCLINE; PRISTINAMYCIN; TOSUFLOXACIN;

ACUTE OTITIS MEDIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; COMMUNITY ACQUIRED PNEUMONIA; COPY NUMBER VARIATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; EPIDEMIC; GENE MUTATION; GENOTYPE; HUMAN; IN VITRO STUDY; JAPAN; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NONHUMAN; NOTE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PYROSEQUENCING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; STEVENS JOHNSON SYNDROME; SYMPTOM;

ANTI-BACTERIAL AGENTS; DISEASE OUTBREAKS; DOXYCYCLINE; FEMALE; HUMANS; MALE; MINOCYCLINE; MYCOPLASMA PNEUMONIAE; PNEUMONIA, MYCOPLASMA;

EID: 84870194434     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis791     Document Type: Note

References (11)

1. Okada T, Morozumi M, Tajima T, et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis 2012; 56:1642-9.
2. Bébéar CM, Pereyre S, Peuchant O. Mycoplasma pneumoniae: Susceptibility and resistance to antibiotics. Future Microbiol 2011; 6:423-31.
3. Jacobs E. Mycoplasma pneumoniae: Now in the focus of clinicians and epidemiologists. Euro Surveill 2012; 17. pii:20084.
4. Lenglet A, Herrador Z, Magiorakos AP, Leitmeyer K, Coulombier D. Surveillance status and recent data for Mycoplasma pneumoniae infections in the European Union and European Economic Area, January 2012. Euro Surveill 2012; 17. pii:20075.
5. Pereyre S, Charron A, Hidalgo-Grass C, et al. The spread of Mycoplasma pneumoniae is polyclonal in both an endemic setting in France and in an epidemic setting in Israel. PLoS One 2012; 7:e38585.
6. Uldum SA, Bangsborg JM, Gahrn-Hansen B, et al. Epidemic of Mycoplasma pneumoniae infection in Denmark, 2010 and 2011. Euro Surveill 2012; 17. pii:20073.
7. Hsieh YC, Tsao KC, Huang CG, et al. Lifethreatening pneumonia caused by macrolide-resistant Mycoplasma pneumoniae. Pediatr Infect Dis J 2012; 31:208-9.
8. Atkinson TP, Boppana S, Theos A, Clements LS, Xiao L, Waites K. Stevens-Johnson syndrome in a boy with macrolideresistant Mycoplasma pneumoniae pneumonia. Pediatrics 2011; 127:e1605-9.
9. Wang Y, Qiu S, Yang G, et al. An outbreak of Mycoplasma pneumoniae caused by a macrolide-resistant isolate in a nursery school in China. Antimicrob Agents Chemother 2012; 56:3748-52.
10. Waites KB, Balish MF, Atkinson TP. New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections. Future Microbiol 2008; 3:635-48.
11. Linde A, Ternhag A, Torner A, Claesson B. Antibiotic prescriptions and laboratoryconfirmed cases of Mycoplasma pneumoniae during the epidemic in Sweden in 2011. Euro Surveill 2012; 17. pii:20082.